---
title: "Harbin Pharmaceutical Group Co.,Ltd. (600664.SH) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600664.SH/overview.md"
symbol: "600664.SH"
name: "Harbin Pharmaceutical Group Co.,Ltd."
parent: "https://longbridge.com/en/quote/600664.SH.md"
datetime: "2026-04-14T22:36:35.741Z"
locales:
  - [en](https://longbridge.com/en/quote/600664.SH/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600664.SH/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600664.SH/overview.md)
---

# Harbin Pharmaceutical Group Co.,Ltd. (600664.SH) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Address | No.68, Limin West 4th Street, Limin Development Zone, Harbin City, Heilongjiang Province |
| Website | [www.hayao.com](https://www.hayao.com) |

## Company Profile

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron vitamin B12 oral solutions, ceftriaxone sodium injections, Qufenggutong gel cream, GNC Vitapak nutrition package, lacidipine tablets, GNC fish oil, GNC children's liquid calcium magnesium zinc IV, and penicillin and cephalosporin antibiotic preparations. The company sells its products under the Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, Puxue, Hayao, and Shiyitang brands.

## Key Executives

| Name | Title |
|------|-------|
| 胡晓萍 | 董事长 |
| 孟晓东 | 董事会秘书 & 副总经理 & 财务负责人 |
| 芦传有 | 总裁 |
| 夏继成 | 副总经理 |
| 李邦东 | 副总经理 |
| 刁广军 | 副总经理 |
| 姜海涛 | 副总经理 |
| 马昆宇 | 证券事务代表 |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| 哈药集团有限公司 | 46.58% | 2025-10-25 |
| 中国证券投资者保护基金有限责任公司 | 2.21% | 2025-10-25 |
| 香港中央结算有限公司 | 0.96% | 2025-10-25 |
| 夏重阳 | 0.91% | 2025-10-25 |
| 余宏标 | 0.72% | 2025-10-25 |
| 招商银行股份有限公司-南方中证1000交易型开放式指数证券投资基金 | 0.55% | 2025-10-25 |
| 哈尔滨天翔伟业投资有限公司 | 0.46% | 2025-10-25 |
| 厦门富诚融资担保有限公司 | 0.34% | 2025-10-25 |
| 招商银行股份有限公司-华夏中证1000交易型开放式指数证券投资基金 | 0.33% | 2025-10-25 |
| 中国工商银行股份有限公司-广发中证1000交易型开放式指数证券投资基金 | 0.25% | 2025-10-25 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Commerce | 10007182104 | 61.46% |
| Industrial | 6276518065 | 38.54% |
| Interdepartmental Offset | -164672121 | % |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Harbin Pharmaceutical Group Co.,Ltd. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Commerce",
        "ratio": 61.46
      },
      {
        "segment": "Industrial",
        "ratio": 38.54
      },
      {
        "segment": "Interdepartmental Offset",
        "ratio": null
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| China | 14717771998 | 90.99% |
| Overseas | 1458084240 | 9.01% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**